Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate

MT Newswires Live

2024/11/11

Unicycive Therapeutics (UNCY) said Monday that the US Food and Drug Administration has accepted its new drug application for oxylanthanum carbonate, and has set a target action date set of June 28, 2025.

The drug is a potential treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, the company said.

Unicycive said it expects to commercialize oxylanthanum carbonate in the second half of 2025, subject to approval.

Unicycive shares were nearly 3% higher in premarket trading.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2482785481"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2482785481\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2482785481?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482785481","market":"fut","top_or_hot":-1,"title":"Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate","media":"MT Newswires Live","content":"<html><body><p> Unicycive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (UNCY) said Monday that the US Food and Drug Administration has accepted its new drug application for oxylanthanum carbonate, and has set a target action date set of June 28, 2025.</p><p>The drug is a potential treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, the company said.</p><p>Unicycive said it expects to commercialize oxylanthanum carbonate in the second half of 2025, subject to approval.</p><p>Unicycive shares were nearly 3% higher in premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-11-11 20:47</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Unicycive <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (UNCY) said Monday that the US Food and Drug Administration has accepted its new drug application for oxylanthanum carbonate, and has set a target action date set of June 28, 2025.</p><p>The drug is a potential treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, the company said.</p><p>Unicycive said it expects to commercialize oxylanthanum carbonate in the second half of 2025, subject to approval.</p><p>Unicycive shares were nearly 3% higher in premarket trading.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2482785481","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482785481","pubTimestamp":1731329225,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Unicycive Therapeutics  said Monday that the US Food and Drug Administration has accepted its new drug application for oxylanthanum carbonate, and has set a target action date set of June 28, 2025.The drug is a potential treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, the company said.Unicycive said it expects to commercialize oxylanthanum carbonate in the second half of 2025, subject to approval.Unicycive shares were nearly 3% higher in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LENZ":"Therapeutics","BK4539":"次新股","BK4139":"生物科技","UNCY":"Unicycive Therapeutics, Inc."},"translate_title":"Unicycive Therapeutics称FDA接受碳酸氧镧新药申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UNCY":1,"LENZ":1},"content_text":"Unicycive Therapeutics (UNCY) said Monday that the US Food and Drug Administration has accepted its new drug application for oxylanthanum carbonate, and has set a target action date set of June 28, 2025.The drug is a potential treatment for hyperphosphatemia in patients with chronic kidney disease on dialysis, the company said.Unicycive said it expects to commercialize oxylanthanum carbonate in the second half of 2025, subject to approval.Unicycive shares were nearly 3% higher in premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}